| Not Yet Recruiting | HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking NCT07264582 | Columbia University | N/A |
| Not Yet Recruiting | Facilitated Telemedicine in the Catholic Health System NCT06483451 | State University of New York at Buffalo | — |
| Not Yet Recruiting | Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland NCT07516912 | University of Zurich | — |
| Not Yet Recruiting | HIV/HBV/HCV Triple Screening in Primary Care NCT07031219 | University of Texas Southwestern Medical Center | N/A |
| Recruiting | Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide NCT07429864 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis) NCT07170748 | MagIA Diagnostics | — |
| Recruiting | Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada NCT07095192 | McGill University | — |
| Not Yet Recruiting | Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East NCT06834178 | Vanessa Stadlbauer-Koellner, MD | — |
| Not Yet Recruiting | Innovate, Involve, Inspire NCT06604182 | Frontline AIDS | N/A |
| Not Yet Recruiting | Current Situation of Health Care in Women With HBV or HCV Infection NCT06579313 | Ruijin Hospital | — |
| Active Not Recruiting | The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City NCT06316739 | North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI) | N/A |
| Completed | Xpert Hepatitis-C Virus (HCV) Test on the GeneXpert Xpress System NCT06508996 | Cepheid | — |
| Active Not Recruiting | Community Intervention to Eliminate HCV Among People Who Use Drugs. NCT05794646 | ANRS, Emerging Infectious Diseases | N/A |
| Unknown | National Prisons Hepatitis Education Project: Research Evaluation NCT05942937 | Kirby Institute | N/A |
| Recruiting | Tools to Identify People At Risk or Already Infected with HIV and HCV NCT06528626 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | N/A |
| Completed | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV NCT05904470 | Atea Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Re NCT05653232 | Johns Hopkins University | N/A |
| Recruiting | Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) NCT05781568 | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis | — |
| Not Yet Recruiting | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid NCT05597800 | Universita di Verona | Phase 2 |
| Completed | The South-East Asian Transgender Health Cohort NCT05454579 | Institute of HIV Research and Innovation Foundation, Thailand | — |
| Completed | Hepatitis C Treatment in Probation and Parole Office NCT05413785 | Jens Rosenau | N/A |
| Unknown | Alpha -1- Microglobulin (α1M) as an Early Biomarker in Renal Extrahepatic Manifestations of HCV-infection NCT05276700 | Assiut University | — |
| Unknown | Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children NCT05854511 | Ain Shams University | Phase 3 |
| Recruiting | A Setting Focus Overdose Prevention Intervention NCT05320835 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Recruiting | Appalachian Partnership to Reduce Disparities (Aim 2) NCT04378439 | Wake Forest University Health Sciences | N/A |
| Completed | Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters NCT05616598 | Benha University | Phase 2 / Phase 3 |
| Terminated | HCV, HBV, HIV Testing During Consultation With Anesthesiologist NCT04286347 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis NCT05181332 | West China Hospital | — |
| Unknown | Prognostic Model of HCV-related Disease Progression After DAAs NCT04631640 | Peking University People's Hospital | — |
| Active Not Recruiting | Integrated HIV Prevention and HCV Care for PWID NCT03981445 | Columbia University | N/A |
| Completed | Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol NCT04971330 | Beckman Coulter, Inc. | — |
| Completed | Utilization of Hepatitis C Positive Kidneys in Negative Recipients NCT03801707 | Ohio State University | Phase 2 / Phase 3 |
| Unknown | Impact of Metabolic Changes and Vitamin D Status on Virological Response in Patients With HCV Infection Treate NCT03820102 | Assiut University | — |
| Unknown | Safety of Sofosbuvir ,Daclatasvir in HCV Patients and RAVS in Resistent and Relapsed Cases NCT03572140 | Assiut University | — |
| Unknown | Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease. NCT03721627 | Mansoura University Children Hospital | Phase 4 |
| Withdrawn | Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet NCT03389061 | Radboud University Medical Center | Phase 4 |
| Completed | Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China NCT03288636 | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 |
| Completed | Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non- NCT03362814 | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 / Phase 3 |
| Withdrawn | A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and NCT03105349 | Fundacion SEIMC-GESIDA | Phase 4 |
| Active Not Recruiting | Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior NCT03221309 | University of Maryland, Baltimore | — |
| Completed | Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects NCT03092375 | University of Florida | Phase 3 |
| Completed | Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening NCT02833298 | Icahn School of Medicine at Mount Sinai | N/A |
| Completed | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Re NCT02692703 | AbbVie | Phase 3 |
| Withdrawn | Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibr NCT02658786 | Institute of Liver and Biliary Sciences, India | — |
| Completed | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection NCT02604017 | AbbVie | Phase 3 |
| Completed | Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV NCT03069001 | Ain Shams University | Phase 4 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavir NCT02446717 | AbbVie | Phase 2 / Phase 3 |
| Completed | Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood NCT02718573 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype NCT02247401 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 Wit NCT02243280 | AbbVie | Phase 2 |
| Completed | Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combina NCT02452814 | Hoffmann-La Roche | — |
| Completed | TD-6450 MAD Study in HCV Infected Subjects NCT02116543 | Theravance Biopharma | Phase 1 |
| Completed | A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclata NCT01842451 | Vertex Pharmaceuticals Incorporated | Phase 2 |
| Completed | A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With R NCT01221298 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 NCT01074008 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fuma NCT00828789 | Tibotec BVBA | Phase 1 |
| Completed | Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Ad NCT00823745 | Pfizer | Phase 1 |
| Completed | TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg E NCT00752544 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Sing NCT00752648 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Terminated | Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocyto NCT00678587 | GlaxoSmithKline | Phase 3 |
| Completed | TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Mu NCT00741169 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b NCT00489385 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |